Raymond James & Associates lessened its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Rating) by 42.9% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 14,144 shares of the biotechnology company's stock after selling 10,648 shares during the period. Raymond James & Associates' holdings in Sarepta Therapeutics were worth $1,563,000 as of its most recent SEC filing.
Other hedge funds have also bought and sold shares of the company. Captrust Financial Advisors boosted its stake in shares of Sarepta Therapeutics by 3.1% in the second quarter. Captrust Financial Advisors now owns 3,534 shares of the biotechnology company's stock worth $265,000 after acquiring an additional 107 shares during the period. M&T Bank Corp boosted its stake in Sarepta Therapeutics by 2.8% during the second quarter. M&T Bank Corp now owns 6,737 shares of the biotechnology company's stock valued at $505,000 after buying an additional 183 shares during the last quarter. Macquarie Group Ltd. boosted its stake in Sarepta Therapeutics by 0.6% during the second quarter. Macquarie Group Ltd. now owns 37,660 shares of the biotechnology company's stock valued at $2,823,000 after buying an additional 236 shares during the last quarter. Great West Life Assurance Co. Can boosted its stake in Sarepta Therapeutics by 6.6% during the first quarter. Great West Life Assurance Co. Can now owns 4,541 shares of the biotechnology company's stock valued at $377,000 after buying an additional 281 shares during the last quarter. Finally, Fox Run Management L.L.C. boosted its stake in Sarepta Therapeutics by 4.7% during the second quarter. Fox Run Management L.L.C. now owns 7,626 shares of the biotechnology company's stock valued at $572,000 after buying an additional 341 shares during the last quarter. Institutional investors own 87.31% of the company's stock.
Get
Sarepta Therapeutics alerts:
Sarepta Therapeutics Trading Down 4.1 %
SRPT opened at $123.16 on Thursday. The stock's fifty day moving average is $123.01 and its two-hundred day moving average is $111.68. The company has a market capitalization of $10.81 billion, a P/E ratio of -15.00 and a beta of 1.04. Sarepta Therapeutics, Inc. has a 52 week low of $61.28 and a 52 week high of $134.08. The company has a quick ratio of 3.99, a current ratio of 4.36 and a debt-to-equity ratio of 3.58.
Sarepta Therapeutics (NASDAQ:SRPT – Get Rating) last released its quarterly earnings data on Wednesday, November 2nd. The biotechnology company reported ($2.94) EPS for the quarter, missing the consensus estimate of ($1.21) by ($1.73). The firm had revenue of $230.30 million for the quarter, compared to analysts' expectations of $234.55 million. Sarepta Therapeutics had a negative return on equity of 97.37% and a negative net
margin of 81.76%. The company's revenue for the quarter was up 21.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.60) earnings per share. Analysts forecast that Sarepta Therapeutics, Inc. will post -8.09 earnings per share for the current year.
Analyst Upgrades and Downgrades
SRPT has been the subject of a number of research reports. The Goldman Sachs Group increased their price target on Sarepta Therapeutics from $152.00 to $171.00 and gave the company a "buy" rating in a research note on Thursday, November 3rd. Needham & Company LLC increased their price target on Sarepta Therapeutics from $158.00 to $160.00 and gave the company a "buy" rating in a research note on Tuesday, January 10th. Royal Bank of Canada dropped their price target on Sarepta Therapeutics from $193.00 to $190.00 and set an "outperform" rating for the company in a research note on Thursday, November 3rd. SVB Leerink restated an "outperform" rating and set a $160.00 price objective on shares of Sarepta Therapeutics in a research report on Friday, January 20th. Finally, UBS Group upgraded Sarepta Therapeutics from a "neutral" rating to a "buy" rating and upped their price objective for the company from $100.00 to $158.00 in a research report on Friday, December 16th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $150.14.
Insiders Place Their Bets
In other Sarepta Therapeutics news, Director Stephen Mayo sold 858 shares of the firm's stock in a transaction on Thursday, November 17th. The stock was sold at an average price of $109.92, for a total transaction of $94,311.36. Following the transaction, the director now directly owns 6,387 shares in the company, valued at approximately $702,059.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 6.40% of the stock is currently owned by company insiders.
Sarepta Therapeutics Company Profile
(Get Rating)
Sarepta Therapeutics, Inc is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.
Read More
- Get a free copy of the StockNews.com research report on Sarepta Therapeutics (SRPT)
- AMD Is Still One Of The Best Semiconductor Stocks Out There
- Two Dividend Kings: Johnson & Johnson or Abbott Laboratories?
- Is The Bottom In For Cyber-Security Stocks?
- Union Pacific, Norfolk Southern Pull into Buying Zone
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
